Sökning: onr:"swepub:oai:gup.ub.gu.se/106846" >
Impact of short-ter...
-
Jin, Tao,1973Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research
(författare)
Impact of short-term therapies with biologics on prothrombotic biomarkers in rheumatoid arthritis.
- Artikel/kapitelEngelska2009
Förlag, utgivningsår, omfång ...
Nummerbeteckningar
-
LIBRIS-ID:oai:gup.ub.gu.se/106846
-
https://gup.ub.gu.se/publication/106846URI
Kompletterande språkuppgifter
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
BACKGROUND: Imbalance of haemostasis in patients with rheumatoid arthritis (RA) contributes to future risk of cardiovascular diseases (CVD). Prothrombotic molecules, e.g. fibrinogen, D-dimer, and tPA are elevated in plasma of RA patients, being associated to CVD. There is no imformation about the influence of biological drugs, e.g. anti-CD20 and tumor necrosis factor (TNF) antibodies on these prothrombotic molecules. OBJECTIVE: To assess whether anti-TNF and anti-CD20 therapies modify the profiles of cardiovascular risk factors in patients with RA. METHODS: The expression of prothrombotic molecules in plasma was investigated in 10 RA patients before and after treatment with TNF-alpha antibodies and in another 12 RA patients before and after anti-CD20 treatment. RESULTS: Both anti-TNF and anti-CD20 infusions gave rise to clear clinical improvement. However, only anti-CD20 infusion significantly (p=0.05) reduced concentration of fibrinogen (p=0.05), D-dimer (p<0.001), as well as tPA levels (p<0.01). In contrast, in TNF antibody treated patients only tPA levels were significantly decreased following the treatment (p<0.05). CONCLUSIONS: Infusion of CD20 antibodies to the patients with active RA led to a clearly reduced plasma levels of predictors of CVD indicating that this treatment, apart from its anti-inflammatory properties, may reduce the risk for future CVD in RA.
Ämnesord och genrebeteckningar
-
Adult
-
Aged
-
Antibodies
-
therapeutic use
-
Antibodies
-
Monoclonal
-
therapeutic use
-
Antigens
-
CD20
-
immunology
-
Antirheumatic Agents
-
therapeutic use
-
Arthritis
-
Rheumatoid
-
blood
-
drug therapy
-
C-Reactive Protein
-
metabolism
-
Cardiovascular Diseases
-
Dose-Response Relationship
-
Drug
-
Female
-
Fibrin Fibrinogen Degradation Products
-
metabolism
-
Fibrinogen
-
metabolism
-
Humans
-
Male
-
Middle Aged
-
Plasminogen Activator Inhibitor 1
-
blood
-
Risk Factors
-
Tissue Plasminogen Activator
-
blood
-
Tumor Necrosis Factor-alpha
-
antagonists & inhibitors
-
immunology
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Bokarewa, Maria,1963Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research(Swepub:gu)xbokma
(författare)
-
Amu, Sylvie,1978
(författare)
-
Tarkowski, Andrej,1951Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning,Institute of Medicine, Department of Rheumatology and Inflammation Research(Swepub:gu)xtaand
(författare)
-
Göteborgs universitetInstitutionen för medicin, avdelningen för reumatologi och inflammationsforskning
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Clinical and experimental rheumatology27:3, s. 491-40392-856X
Internetlänk
Hitta via bibliotek
Till lärosätets databas